NLRP3 and B-cell chronic lymphocytic leukemia: Parthenolide, the first natural product that directly targets Cas-1 and NLRP3, has recently shown versatile inhibitory actions in different pathologies, such as AD [118]; similarly, ibrutinib, an FDA-approved natural products for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma, has shown potential effects in preventing and reducing neuroinflammatory symptoms of AD, by targeting NLRP3/Cas-1 signaling [118].